The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy

Luigi Bartalena a, Lelio Baldeschi b, Kostas Boboridis c, Anja Eckstein d, George J. Kahaly e, Claudio Marcocci f, Petros Perros g, Mario Salvi h, Wilmar M. Wiersinga i on behalf of the European Group on Graves’ Orbitopathy (EUGOGO)

a Department of Clinical and Experimental Medicine, University of Insubria, Endocrine Unit, Ospedale di Circolo, Varese, Italy; b Department of Ophthalmology, Hospital Saint Luc, Catholic University of Louvain, Brussels, Belgium; c Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; d Zentrum für Augenheilkunde, Universitätsklinikum Essen, Essen, and e Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany; f Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; g Department of Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; h Graves’ Orbitopathy Center, Endocrinology, Fondazione Ca’ Granda IRCCS, University of Milan, Milan, Italy; i Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Key Words
Cyclosporine · Eyelid surgery · Glucocorticoids · Graves’ orbitopathy · Orbital decompression · Orbital radiotherapy · Rituximab · Selenium · Squint surgery

Abstract
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient’s quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5–5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.

© 2016 European Thyroid Association
Published by S. Karger AG, Basel
Introduction

In 2008, EUGOGO published a consensus statement on the management of Graves' orbitopathy (GO) simultaneously in the European Journal of Endocrinology and in Thyroid [1, 2]. The statement was received very well [3] and has been in widespread use ever since. Guidelines for the management of hyperthyroidism by the American Thyroid Association and American Association of Clinical Endocrinologists were published in 2011; recommendations were made on how hyperthyroidism should be managed in patients with GO, though not on the treatment of GO itself [4]. A number of randomized clinical trials on the treatment of GO have been published in the last few years, and their outcome has influenced substantially the management of GO patients. Consequently, the European Thyroid Association (ETA) commissioned EUGOGO to provide guidelines for the management of GO.

New epidemiological studies provide fairly consistent figures on the prevalence and incidence of GO in the general population and in patients presenting with Graves’ hyperthyroidism. The incidence of Graves' hyperthyroidism in the general population of Sweden is 210 per million per year, with a female: male ratio of 3.9:1 and a peak incidence between 40 and 60 years [5]. The incidence of GO is 42.2 per million per year (20.1% of the incidence of Graves’ hyperthyroidism) [5]. In Denmark, the incidence of moderate-to-severe and very severe GO is 16.1 per million per year in the general population, with a female: male ratio of 5:1 and a peak incidence between 40 and 60 years [6]. The prevalence of moderate-to-severe and very severe GO in patients with Graves’ hyperthyroidism was 4.9% in the Danish study, which was not dissimilar from the 6.1% observed in a single-center study in Italy [7]. The latter study is of much clinical interest because it clearly demonstrates that most patients with Graves’ hyperthyroidism (>80%) without GO at presentation who are treated with antithyroid drugs do not develop GO after an 18-month follow-up and that mild GO disappears spontaneously in the majority of cases. A study comparing characteristics of referrals to EUGOGO centers reveals a secular trend to less active and less severe GO in patients referred in 2012 as compared to 2000 [8].

Methods

Literature Search
Data acquisition was based on PubMed search strategies, with particular regard to papers published after the publication of the previous EUGOGO consensus statement (2008–2015) [1, 2]. Furthermore, the list of references of relevant citations and chapters of major textbooks were evaluated for any additional appropriate citation.

Grading
The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system was used to make recommendations and express the quality of the evidence [9]. The working group used the following coding system: (1) indicates a strong recommendation and is associated with the phrase ‘we recommend’; (2) denotes a weak recommendation and is associated with the phrase ‘we suggest’. Evidence grading: ○○○○ = very low quality; ○○○○○ = low quality; ○○○○○ = moderate quality, and ○○○○○ = high quality. The draft was discussed by the whole EUGOGO group and then posted on the ETA website for 2 weeks inviting comments from ETA members.

Recommendations

A summary of the recommendations is presented in table 1.

What Should Be the Clinicians’ General Approach to Patients with GO?
Multidomain quality of life (QoL) surveys (e.g. SF-36) show that people with GO have substantially reduced QoL, equivalent to having diabetes or certain cancers [10]. Optimal treatment has been shown to improve QoL in such patients, using a validated, GO-specific QoL tool (GOQoL) [11]. Direct and indirect costs (due to disability and/or unemployment) are significant [12]. To achieve best outcomes, clinicians need to provide a patient-focused comprehensive plan with due attention not only to the clinical components of the disease, but also to the impact of GO on the individual’s QoL and psychosocial well-being.

Recommendation
1 We recommend a patient-focused approach to the treatment of patients with GO, which encompasses the effects of the disease and its treatment on QoL and psychosocial well-being. Use of GOQoL, a disease-specific and validated tool, is recommended in routine clinical practice and is available in several languages (www.eugogo.eu).

Why and How Should Activity and Severity of GO Be Assessed?
Selecting the most appropriate treatment for individual patients depends on the activity and severity of the eye...
Table 1. Summary of recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength of recommendation and level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 General</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend a patient-focused approach to the treatment of patients with GO, which encompasses the effects of the disease and its treatment on QoL and psychosocial well-being. Use of GOQoL, a disease-specific and validated tool, is recommended in routine clinical practice and is available in several languages (<a href="http://www.eugogo.eu">www.eugogo.eu</a>).</td>
<td></td>
</tr>
<tr>
<td>2 Assessment</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that activity and severity of GO be assessed according to standardized criteria and GO be categorized as active or inactive and as mild, moderate to severe or sight threatening, as listed in table 2.</td>
<td></td>
</tr>
<tr>
<td>3 Specialized centers</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that primary-care physicians, general practitioners, general internists and specialists should refer patients with GO to combined thyroid-eye clinics or specialized centers providing endocrinological and ophthalmological expertise – except for the mildest cases improving with normalizing thyroid status and local lubricants.</td>
<td></td>
</tr>
<tr>
<td>4 Quit smoking</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that physicians urge all patients with Graves’ hyperthyroidism, irrespective of the presence/absence of GO, to refrain from smoking, if necessary with the help of specialized smoking cessation programs or clinics.</td>
<td></td>
</tr>
<tr>
<td>5 Thyroid dysfunction</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that euthyroidism be promptly restored and stably maintained in all patients with GO.</td>
<td></td>
</tr>
<tr>
<td>6 Steroid prophylaxis</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that oral prednisone prophylaxis, starting with a daily dose of 0.3–0.5 mg prednisone/kg body weight, be given in radiiodine-treated patients at high risk of progression or de novo development of GO. Lower-dose prednisone can be used in low-risk patients. Patients with inactive GO can safely receive radiiodine without steroid cover, as long as hypothyroidism is avoided, if other risk factors for GO progression, particularly smoking, are absent.</td>
<td></td>
</tr>
<tr>
<td>7 Topical treatments</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that all patients with GO be evaluated for ocular surface disease and treated extensively with nonpreserved artificial tears with osmoprotective properties at all times in the course of their disease unless corneal exposure requires the higher protection that gels or ointment can offer especially at nighttime.</td>
<td></td>
</tr>
<tr>
<td>8 Mild GO</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that mild GO be treated with local treatments and general measures to control risk factors; if the impact of the disease on QoL outweighs risks, then immunosuppressive therapy (for active GO) or rehabilitative surgery (for inactive GO) may be justified.</td>
<td></td>
</tr>
<tr>
<td>9 Selenium supplementation for mild GO</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that a 6-month selenium supplementation be given to patients with mild GO of relatively short duration, because it improves eye manifestations and QoL and prevents GO progression to more severe forms.</td>
<td></td>
</tr>
<tr>
<td>10 First-line treatment for moderate-to-severe and active GO</td>
<td>1, Ø Ø Ø</td>
</tr>
<tr>
<td>We recommend that high-dose intravenous GCs be considered as first-line treatment for moderate-to-severe and active GO. Intravenous GC therapy should be performed in experienced centers that can safely manage potentially serious adverse events.</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (continued)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength of recommendation and level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Cumulative dose of intravenous GCs</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>12 Cumulative dose of intravenous GCs 2</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>13 GC withdrawal</td>
<td>2, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>14 Second-line treatments for moderate-to-severe and active GO</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>15 Rehabilitative surgery</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>16 Treatment of sight-threatening GO 1</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
<tr>
<td>17 Treatment of sight-threatening GO 2</td>
<td>1, Ø Ø Ø Ø</td>
</tr>
</tbody>
</table>
changes. Activity is easily measured by the clinical activity score (CAS) [13]. A CAS ≥3/7 is indicative of active GO. Severity is rated as mild, moderate to severe and sight threatening (or very severe). Criteria for activity and severity assessment are reported in table 2 and have not been changed since 2008 [1, 2].

Recommendation
2 We recommend that activity and severity of GO be assessed according to standardized criteria and that GO be categorized as active or inactive and as mild, moderate to severe or sight threatening, as listed in table 2. (1, ∅ ∅ ∅ ∅)

Should All Patients with GO Be Referred to Specialized Centers or Thyroid-Eye Clinics?
GO appears to be less frequent and milder in patients with newly diagnosed Graves’ hyperthyroidism now than some years ago [7] and rarely progressive to more severe forms [14]. Also, patients referred to tertiary referral centers have less severe and, more often, inactive GO than in the past [8]. These trends may reflect earlier diagnosis of GO and more effective management strategies of Graves’ disease by endocrinologists and ophthalmologists, and underscore the role of specialized centers for early clinical care of these patients. Referral patterns vary among countries and health care systems, and further delineation of pathways of care by national bodies may facilitate this progress [15]. On the other hand, there are still patients presenting with recurrences of inflammatory signs of GO and complications due to inadequate evaluation of clinical and imaging features of GO and inappropriate treatment strategies [16]. In a large nationwide survey in the UK, only 56% of responders were satisfied with the treatment they received for GO; however, those who had attended a specialist GO clinic were more satisfied than those who had not attended a specialist clinic (67 vs. 52%, p < 0.05) [17].

Recommendation
3 We recommend that primary-care physicians, general practitioners, general internists and specialists should refer patients with GO to combined thyroid-eye clinics or specialized centers providing endocrinological and ophthalmological expertise – except for the mildest cases improving with normalizing thyroid status and local lubricants. (1, ∅ ∅ ∅ ∅)

### Table 2. Assessment of GO activity and severity

**GO activity assessment according CAS**

1 Spontaneous retrobulbar pain
2 Pain on attempted upward or downward gaze
3 Redness of eyelids
4 Redness of conjunctiva
5 Swelling of caruncle or plica
6 Swelling of eyelids
7 Swelling of conjunctiva (chemosis)

* Inactive GO = CAS <3
* Active GO = CAS ≥3

**GO severity assessment according to NOSPECS**

No signs or symptoms
Only signs, no symptoms: lid aperture (distance between
lid margins in mm with patient looking in primary
position, sitting relaxed, with distant fixation)
Soft tissue involvement: swelling/redness of the eyes
Proptosis: exophthalmos (in mm: using the same Hertel
exophthalmometer and same intercanthal distance for an
individual patient)
Extraocular muscle involvement: eye muscle ductions in
degrees; subjective diplopia score – intermittent
(i.e. diplopia when tired or when first awakening),
inconstant (i.e. diplopia at extremes of gaze) and constant
(i.e. continuous diplopia in primary or reading position)
Corneal involvement: absent/punctuate keratopathy,
ulcer
Sight loss (due to optic nerve involvement): best-corrected
visual acuity, color vision, optic disk, relative afferent
papillary defect, visual fields (if optic nerve compression
is suspected)

**GO severity assessment according to EUGOGO**

* Mild GO
  Patients whose features of GO have only a minor impact
  on daily life insufficient to justify immunosuppressive or
  surgical treatment. They usually have one or more of the
  following: minor lid retraction (<2 mm), mild soft-tissue
  involvement, exophthalmos <3 mm above normal for race
  and gender, no or intermittent diplopia and corneal
  exposure responsive to lubricants

* Moderate-to-severe GO
  Patients without sight-threatening GO whose eye disease
  has sufficient impact on daily life to justify the risks of
  immunosuppression (if active) or surgical intervention (if
  inactive). They usually have two or more of the following:
  lid retraction ≥2 mm, moderate or severe soft-tissue
  involvement, or exophthalmos ≥3 mm above normal for
  race and gender, inconstant or constant diplopia

* Sight-threatening GO (very severe GO)
  Patients with DON and/or corneal breakdown
How Should Risk Factors for GO Occurrence or Progression Be Managed?

Smoking

The association between smoking and GO is well established [18], including the following observations: (i) smokers have more severe GO than nonsmokers [19, 20]; (ii) smokers are more likely to show progression or de novo occurrence of GO after radioiodine treatment [21, 22]; (iii) smoking delays or worsens the outcome of immunosuppressive treatment for GO [23, 24], and (iv) in a retrospective study, smoking cessation was associated with a better outcome of GO (table 3) [25]. Accordingly, all patients with Graves’ hyperthyroidism, irrespective of the presence or absence of GO, should be urged to quit smoking.

Recommendation

4 We recommend that physicians urge all patients with Graves’ hyperthyroidism, irrespective of the presence/absence of GO, to refrain from smoking, if necessary with the help of specialized smoking cessation programs or clinics.

Thyroid Dysfunction and Treatment

Restoration and maintenance of euthyroidism is imperative in the presence of GO, because both hyper- and hypothyroidism have a negative impact on GO (table 4) [26, 27]. Antithyroid drugs and thyroidectomy per se do not appear to affect the natural course of GO (table 5) [21, 28]. Radioiodine treatment confers a small, but definite risk of exacerbation or de novo development of GO [21, 29, 30], particularly in smokers, in severe hyperthyroidism (high free thyroid hormone levels and/or TSH receptor autoantibodies) [22, 30] and hyperthyroidism of recent onset (table 5) [31]. This detrimental effect can be nearly always prevented in patients at risk by oral prednisone prophylaxis given concomitantly with radioiodine treatment. The original schedule used a starting dose of 0.3–0.5 mg prednisone/kg body weight per day, and duration of treatment was 3 months [21]. It was subsequently shown that a 6-week course using lower doses (starting dose, 0.2 mg prednisone/kg body weight per day) was equally effective (table 5) [32–34]. However, a recent randomized prospective study from Japan showed that the low-dose oral prednisone schedule may not always be sufficient [35]. Vigilance is required to anticipate and prevent thyroid dysfunction after radioiodine treatment; if dysthyroidism occurs, it should be corrected promptly (table 4) [36, 37]. Antithyroid drugs, thyroidectomy and radioiodine treatment (with steroid prophylaxis if indicated) are effective treatments for hyperthyroidism, and there is no evidence of a substantial

---

**Table 3. Evidence supporting a negative effect of smoking habits on GO**

<table>
<thead>
<tr>
<th>Finding</th>
<th>Type of study</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higher prevalence of smokers in Graves’ patients with GO than in those without GO</td>
<td>Observational study</td>
<td>19, 20</td>
</tr>
<tr>
<td>Smokers tend to have more severe GO</td>
<td>Consecutive entry case-control study</td>
<td>20</td>
</tr>
<tr>
<td>Smokers are more likely to have progression or de novo occurrence of GO after radioiodine treatment</td>
<td>Randomized clinical trial</td>
<td>21, 22</td>
</tr>
<tr>
<td>Smoking delays or worsens the outcome of immunosuppressive treatment for GO</td>
<td>Randomized clinical trial</td>
<td>23</td>
</tr>
<tr>
<td>Refraining from smoking might reduce the risk of developing exophthalmos and diplopia</td>
<td>Retrospective study</td>
<td>25</td>
</tr>
</tbody>
</table>

**Table 4. Evidence supporting a negative effect of thyroid dysfunction on GO**

<table>
<thead>
<tr>
<th>Finding</th>
<th>Type of study</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restoration of euthyroidism with antithyroid drugs is associated with an improvement in GO</td>
<td>Prospective study</td>
<td>27</td>
</tr>
<tr>
<td>Occurrence of GO may be associated with uncontrolled hypothyroidism</td>
<td>Retrospective study</td>
<td>26</td>
</tr>
<tr>
<td>Late correction of hypothyroidism after radioiodine treatment is associated with increased risk for GO</td>
<td>Retrospective study</td>
<td>36</td>
</tr>
</tbody>
</table>

---
difference on the impact that they have on GO. The choice between these three options depends on the individual circumstances of patients and their preference [38].

**Recommendations**

5 We recommend that euthyroidism be promptly restored and stably maintained in all patients with GO. (1, ∅ ∅ ∅ ∅)

6 We recommend that oral prednisone prophylaxis, starting with a daily dose of 0.3–0.5 mg prednisone/kg body weight, be given in radiiodine-treated patients at high risk of progression or de novo development of GO. Lower-dose prednisone can be used in low-risk patients. Patients with inactive GO can safely receive radiiodine without steroid cover, as long as hypothyroidism is avoided, if other risk factors for GO progression, particularly smoking, are absent. (1, ∅ ∅ ∅ ∅)

The Rationale for the Use of Topical Treatments at All Times in the Course of GO

Ocular surface inflammatory disease and dry eye are frequent findings in patients with Graves’ hyperthyroidism even before the onset of overt GO [39–43]. In GO, increased palpebral fissure width, exophthalmos, blink rate, lid lag, lagophthalmos, deficit in elevation and poor Bell’s phenomenon can all potentially cause drying of the ocular surface. According to the results of a prospective case series of 17 patients [44], the damage to the ocular surface depends mainly on widened palpebral fissure, which increases ocular surface evaporation resulting in an elevated tear film osmolarity similar to that of keratoconjunctivitis sicca. Rose bengal and lissamine green staining clearly demonstrated a significant presence of drying epithelial cells in early as well as in late GO patients compared to controls. Additionally, a significantly low break-up time was found, though limited to late GO patients [45].

When active GO has been specifically studied, ocular surface damage correlated significantly with a reduced tear secretion. The lacrimal gland physiologically expresses the TSH receptor, which, in active GO, can bind with circulating anti-TSHR autoantibodies and contribute to lacrimal gland impairment [46]. This is an immune-mediated lacrimal gland dysfunction initially characterized by inflammation and followed by gland fibrosis and dropout, manifesting as a secondary Sjögren’s syndrome in long-lasting disease [46–50]. Proteomics of tear fluids demonstrated an upregulation of inflammatory proteins and a downregulation of protective proteins in GO, with a significantly different panel compared to dry-eye patients and controls [51]. Elevated tear osmolarity is the main component of dry eye in GO, leading to symptomatic ocular surface disease that significantly affects QoL [52, 53].

For every form of dry eye, baseline treatment consists of nonpreserved artificial tears containing a demulcent with long retention time, such as sodium hyaluronate, applied several times per day, as required, to protect the ocular surface and control symptoms from the early stages of the disease [54]. Osmoprotective agents offer additional epithelial protection and symptomatic control especially in cases with increased osmolarity as in GO [55, 56].
**Recommendation**

7 We recommend that all patients with GO be evaluated for ocular surface disease and treated extensively with nonpreserved artificial tears with osmoprotective properties at all times in the course of their disease unless corneal exposure requires the higher protection that gels or ointment can offer especially at nighttime.

(1, ∅ ∅ ∅ ∅)

**How Should Mild GO Be Managed?**

In most patients with mild GO, a watchful strategy is sufficient (fig. 1) [1, 2]. Control of thyroid dysfunction, refraining from smoking and local measures (artificial tears or ointments) should be implemented. Occasionally, objectively mild GO has a profound impact on QoL: these cases may be considered as moderate-to-severe GO and offered immunosuppressive treatment or rehabilitative surgery (see the following two sections) [1, 2].

Selenium is incorporated as selenocysteine into several selenoproteins, which have a major role in the maintenance of the cellular redox state [57, 58]. In vivo and in vitro studies have shown that increased generation of reactive oxygen species may be involved in the pathogenesis of GO [59]. The effect of selenium supplementation on the course of mild GO was evaluated in a large, multicenter, randomized, double-blind, placebo-controlled trial [60]. Patients were randomly assigned to 6 months of treatment with sodium selenite (100 μg twice daily, corresponding to 93.6 μg of elemental selenium/day) or placebo. The primary outcomes were changes in the QoL and overall ocular involvement at 6 months. Both improved significantly in the selenium group compared to the placebo group (overall ocular improvement: 61 vs. 36% in the placebo group, p < 0.001), and improvement was maintained at 12 months, after selenium withdrawal; in addition, the rate of progression of GO to more severe

---

**Fig. 1.** Management of GO. For definition of activity and severity, see text and table 2, for local measures, see text.
forms after intervention was significantly lower in the selenium group (7 vs. 26% in the placebo group, p < 0.001) [60]. No selenium-related adverse events were observed. Enrolled patients mostly came from marginally selenium-deficient areas in Europe [61]. Whether selenium supplementation is beneficial and safe also for patients with mild GO residing in selenium-sufficient areas is unclear. In long-standing, inactive, mild GO, there is no evidence that selenium is effective. In these cases, rehabilitative surgery can be performed, as needed [1, 2] (fig. 1).

Recommendations

8 We recommend that mild GO be treated with local treatments and general measures to control risk factors; if the impact of the disease on QoL outweighs risks, then immunosuppressive therapy (for active GO) or rehabilitative surgery (for inactive GO) may be justified.

(1, ∅∅∅∅)

9 We recommend that a 6-month selenium supplementation be given to patients with mild GO of relatively short duration, because it improves eye manifestations and QoL and prevents GO progression to more severe forms.

(1, ∅∅∅∅)

How Should Moderate-to-Severe and Active GO Be Managed?

First-Line Treatment

High-dose systemic glucocorticoids (GCs) are currently the first-line treatment for moderate-to-severe and active GO (fig. 1) [1, 2, 62]. Proof of principle of the efficacy of intravenous GCs was provided by a small randomized clinical trial [favorable outcome in 5 of 6 (83%) GC-treated patients vs. 1 of 9 (11%) placebo-treated patients] [63]. Intravenously administered GCs are more effective and better tolerated than oral GCs (rate of adverse events: 39 vs. 81%, p < 0.001) [1, 2, 64–66]. Several randomized clinical trials found a response rate of approximately 70–80% in patients treated intravenously compared to 50% in those treated orally [62, 64]. Therefore, GCs are preferentially administered intravenously for the treatment of moderate-to-severe and active GO [65, 66]. Intravenous GCs exert their immunosuppressive effect via both nongenomic (quick effect, within minutes) and genomic (long-term effect) pathways [67].

The most common schedule for intravenous GC therapy, based on a randomized clinical trial [68], is a cumulative dose of 4.5 g of methylprednisolone, divided into 12 weekly infusions (6 weekly infusions of 0.5 g, followed by 6 weekly infusions of 0.25 g) [68]. In a recent randomized study, this schedule was compared with a shorter regimen of the same cumulative dose (daily infusion of 0.5 g for 3 days over 2 weeks, followed by a daily infusion of 0.25 g for 3 days over 2 weeks) [69]. The latter protocol was, however, associated with lower efficacy compared to the standard protocol (response rate of 41 vs. 77%; p = 0.0025) and toxicity was higher [69]. In a large, multicenter EUGOGO randomized clinical trial of 159 patients with moderate-to-severe and active GO, three different cumulative doses of methylprednisolone were used (7.47, 4.98 and 2.25 g) over the same time period [70]. CAS decreased significantly with all doses, but the overall ophthalmic improvement was significantly more common using the highest dose (52 vs. 35 and 28% using the other two doses, respectively) [70]. However, the highest dose was associated with a slightly greater frequency of adverse events. The authors concluded that a cumulative dose of 4.5–5 g could be used in most cases, while the highest dose should be reserved to more severe cases [70]. High daily doses (0.5–1.0 g) administered several times per week for 2 consecutive weeks are usually necessary in patients with sight-threatening GO [71], but high single (>0.5 g) and/or cumulative doses (>8 g) of intravenous GCs are associated with a 2-fold higher rate of adverse events (56 vs. 28%, p < 0.001, and 52 vs. 33%, p = 0.034, respectively) [72], including serious cardiovascular, cerebrovascular and hepatic toxicity [62, 64]. A recent review of 14 studies including 1,045 GO patients determined the morbidity and mortality of intravenous GC therapy to be 6.5 and 0.6%, respectively [62]. Safety data suggest that single doses should not exceed 0.75 g [73], cumulative doses should be less than 8.0 g, and consecutive-day therapy should be avoided [62]. Assessment of liver enzymes, viral markers for hepatitis, fasting serum glucose levels and hepatic ultrasound is advised prior to GC therapy [62, 65, 73]. Contraindications to therapy include evidence of recent viral hepatitis, significant hepatic dysfunction, severe cardiovascular morbidity, uncontrolled hypertension, psychiatric disorders and inadequately controlled diabetes [62, 69]. Liver enzymes, glucose levels and blood pressure are best monitored monthly during treatment. Proton pump inhibitors to prevent peptic ulcer are recommended, and bone protection may be required, especially in patients with multiple risk factors for osteoporosis.

Guidelines for GO Management

Eur Thyroid J 2016;5:9–26
DOI: 10.1159/000443828
**Recommendations**

10 We recommend that high-dose intravenous GCs be considered as first-line treatment for moderate-to-severe and active GO. Intravenous GC therapy should be performed in experienced centers that can safely manage potentially serious adverse events.

(1, ∅ ∅ ∅ ∅)

11 We recommend that the cumulative dose of intravenous GCs should not exceed 8.0 g and that GO patients with evidence of recent viral hepatitis, significant hepatic dysfunction, severe cardiovascular morbidity or psychiatric disorders should not be administered intravenous GCs; diabetes and hypertension should be well controlled before starting treatment.

(1, ∅ ∅ ∅)

12 We recommend an intermediate-dose schedule of methylprednisolone, i.e. a starting dose of 0.5 g once weekly for 6 weeks, followed by 0.25 g once weekly for 6 weeks (4.5 g cumulative dose) in most cases of moderate-to-severe and active GO. High-dose regimens, i.e. a starting dose of 0.75 g once weekly for 6 weeks, followed by 0.5 g once weekly for 6 weeks (7.5 g cumulative dose) should be reserved for the worst cases within the moderate-to-severe spectrum.

(1, ∅ ∅ ∅ ∅)

**What Are the Indications for Withdrawing GCs?**

Some patients respond early to intravenous GCs, while others take longer. Anecdotal experience suggests that early (within 2 weeks) response may be predictive of long-term response to GCs. Current evidence suggests that intravenous GC pulse should not continue for more than 12 weeks and the cumulative dose of methylprednisolone should not exceed 8 g (recommendations 11 and 12), thus defining broad boundaries for safe use of high-dose intravenous GC pulse therapy. However, adverse effects of GCs vary between individuals [73] and often occur with the recommended regimens. Maintaining a balance between benefit and harm is an important task for clinicians supervising GC therapy and may change during the course of treatment. When the balance tips against continuation of GCs, the options are to discontinue medical therapy or consider another form of treatment.

**Recommendation**

13 We suggest that clinicians should monitor each individual patient receiving GC therapy for response to treatment and adverse effects. When side effects outweigh benefits, clinicians should consider withdrawal of GC treatment in favor of another modality or watchful monitoring.

(2, ∅ ∅ ∅ ∅)

---

**Fig. 2.** First-line therapeutic approach in patients with moderate-to-severe and active GO and options in the case of an absent or incomplete response to treatment. Rx = Radiotherapy.
Second-Line Treatments

Although intravenous GCs are the first-line and generally effective treatment for moderate-to-severe and active GO, partial or inadequate responses or recurrences are not uncommon [70]. Management of patients experiencing medical treatment failure to intravenous GCs is a major challenge [74] due to the limited evidence about the efficacy of alternative treatment regimens in this clinical setting. This may be further complicated if patients do not wish to recommence GC or when they have experienced troublesome side effects of GC therapy.

Several options can be planned if GO is still active:
(a) A second course of intravenous GCs can be administered if the patient tolerates it and a cumulative dose of 8 g of methylprednisolone is not exceeded (fig. 2) [1, 2, 70, 72].

(b) Orbital radiotherapy has been shown in randomized clinical trials to be more effective than sham irradiation in improving diplopia and range of ductions [75, 76]. One randomized clinical trial has questioned its efficacy [77]. In another randomized clinical trial, orbital radiotherapy was shown to be as effective as oral GCs [78]. Orbital radiotherapy has been shown in randomized clinical trials to synergistically potentiate the effects of oral GCs [79, 80]. It is possible that orbital radiotherapy may also potentiate the effects of intravenous GCs, but evidence on this specific issue is currently missing [81]. A cumulative dose of 20 Gy per orbit fractionated in 10 daily doses given over a 2-week period is commonly used [1, 2], but an alternative regimen of 1 Gy per week over a 20-week period was shown to be equally effective and better tolerated [82, 83]. Mild and transient exacerbation of ocular symptoms induced by irradiation may occur, but can be controlled by concomitant low-dose oral GC administration [81]. Data on long-term safety are reassuring [84–86].

(c) Two randomized controlled studies have demonstrated that the combination of cyclosporine with oral GCs was more effective than either treatment alone in patients with moderate-to-severe and active GO [87, 88]. In one study, two groups of patients were treated with oral prednisone (starting dose, 100 mg per day) in decreasing doses for 3 months, alone or in combination with cyclosporine (starting dose, 5 mg/kg body weight), which was then continued up to 12 months [87]. Combined treatment was associated with a better ocular outcome and a significantly lower rate of recurrences of GO [87]. In the second study, patients who did not respond adequately to single-drug therapy, either prednisone (starting dose, 60 mg per day) or cyclosporine (starting dose, 7.5 mg/kg body weight), received also the second drug: about 60% of nonresponders to single-drug therapy had a response to combined-drug therapy [88]. The most common adverse events related to cyclosporine are dose-dependent liver and renal toxicities, and gingival hyperplasia. In one study on the use of cyclosporine for GO, a mild, nonsignificant increase in serum creatinine levels was noted in all patients, and 1 case of Klebsiella pneumoniae infection was observed in the cyclosporine group [87]. In the other study, 1 patient had an irreversible rise in the plasma creatinine concentration, and 6 patients had a transient rise in blood pressure [88].

(d) Rituximab has been used off-label in autoimmune disorders because of its direct B-cell-depleting action and modulation of all B-cell functions [89, 90]. In earlier noncontrolled reports [91, 92], rituximab was employed in patients with active GO unresponsive to intravenous GCs, and in a small open study [93] it was given as a first-line treatment, with disease inactivation as the end point. The results of two small-sized randomized clinical trials of rituximab in moderate-to-severe and active GO from single centers have recently been published. In one study of 31 patients treated with rituximab (n = 15) or intravenous GCs (n = 16), GO was more significantly inactivated after rituximab (100 vs. 69% after intravenous GCs); disease reactivation never occurred after rituximab, although it did in 31% of patients after intravenous GCs [94]. Rituximab was slightly more effective than intravenous GCs on ocular motility and QoL [94]. Rituximab was given at a dose of 1,000 mg (administered twice over 2 weeks) in the first 5 patients, and 500 mg as a single injection in the remaining 10 patients, based on the observation of a complete B-cell depletion after only 100 mg of rituximab [95]. In the second study, rituximab (1,000 mg twice over 2 weeks) was given to 13 patients and compared to placebo (n = 12) [96]. This study failed to demonstrate a difference in outcomes between rituximab and placebo [96]. Two patients, who had no overt or impending dysthyroid optic neuropathy (DON) prior to treatment, developed DON after rituximab. The reasons for the divergent outcomes in the two studies remain elusive. A major difference that may have negatively influenced the outcome of the latter compared to the former study is a longer disease duration. In view of these conflicting results, larger multicenter studies are warranted to establish whether rituximab could be considered a first-line treatment for moderate-to-severe and active GO, as an alternative to high-dose GCs. However, the results of one out of two randomized clinical trials and few nonrandomized studies suggest that rituximab...
could be considered as a second-line therapeutic option after failure of intravenous GC treatment. Rituximab has been employed successfully in 10 patients with DON [97–99], but the available evidence from one of the randomized studies [96], as well as a case report of a patient with GC-resistant GO [100], suggests that progression of DON may also occur after rituximab. Based on the above, rituximab should not be used in patients with impending DON or long duration of disease. Infusion-related reactions are the most frequently reported short-term side effects of rituximab [101], may occur in about 10–30% of patients at first infusion and can be minimized by premedication with antihistamine and 100 mg of hydrocortisone prior to infusion. Rarely, transient, but significant peri orbital edema and inflammation may occur. A recent review of over 3,000 patients with rheumatoid arthritis showed comparable serious infection rates in those treated with rituximab versus placebo plus methotrexate over 9.5 years of observation [102]. Progressive multifocal leukoencephalopathy has been reported in patients receiving rituximab associated with other immunosuppressants, mostly in patients with systemic lupus erythematosus [103].

(e) Watchful monitoring may be indicated in some patients after GC withdrawal, because ocular findings of orbital vascular congestion can show similarities with active GO, such as eyelid edema, eyelid and conjunctival redness, and chemosis more frequently in patients with longer disease duration. Thus, patients with high CAS poorly responsive to immunosuppressive treatment and relatively long-lasting disease should be evaluated for orbital vascular congestion, because orbital decompression can improve clinical features by increasing the venous outflow of the orbit [16].

All of the above options are worth considering in view of the current limited evidence. Shared decision-making is an appropriate way of selecting the most suitable option, because it balances benefits against potential side effects of each option in the context of the individual patient and considers the patient’s comorbidities, personal circumstances and values, and impact of the disease on QoL [104].

**Recommendation**

14 We recommend shared decision-making as an appropriate approach to select a second-line therapy in patients with moderate-to-severe and active GO. (1, ∅ ∅ ∅ ∅)

Other Treatments

Periocular injections of triamcinolone acetate (40 mg/ml) were shown to reduce diplopia and extraocular muscle size in recent-onset and active GO by two randomized clinical trials, with no serious local or systemic adverse effects [105, 106]. Subconjunctival triamcinolone injections were effective in resolving eyelid swelling and mild degrees of retraction in recent-onset GO, the only side effect being a transient elevation in intraocular pressure [107].

Treatment with other drugs, including azathioprine [108], ciamexone [109] and somatostatin analogues [110–113], has marginal or unproven beneficial effects on GO. Their use cannot be recommended for moderate-to-severe and active GO. Intravenous immunoglobulins were found to be comparably effective to high doses of oral GCs in one randomized and in one prospective controlled trial [114, 115]; however, the high costs and, at that time, putative viral (hepatitis and HIV) transfer markedly limited the widespread use of this cumbersome treatment.

In active disease with possibly variable (small to moderate: usually <15 prismatic diopters) squint angle, prismatic lenses can be of help in restoring fusion in the case of primary gaze diplopia or compensatory torticollis. Botulinum toxin can also be beneficial to treat upper-lid retraction and lagophthalmos. The use of botulinum introduces an additional variable that needs to be considered when following the patients [116].

**How Should Moderate-to-Severe and Inactive GO Be Managed?**

This condition can require different degrees of surgical rehabilitation. The type and extension of surgeries depends on the amount of disfigurement and/or functional impairment that persists in the postinflammatory phase of the disease. Decompression surgery, strabismus surgery, lid lengthening and cosmetic periorbital surgeries can be necessary and should be performed in the given order as the preceding step may influence the necessity or the extension of the step that follows [117].

**Decompression Surgery**

Different techniques of decompression [118], lid lengthening and cosmetic surgery can be applied depending on the severity of the orbitopathy, anatomical background, concomitant diseases, patient expectations and social/cultural background. No technique fits all. Minimally invasive approaches are preferred. Decompression surgery is aimed at reducing the raised intraorbital pressure which is responsible for the typical signs and symptoms of the disease. This is achieved by enlarging the bony...
orbit (different degrees of extension of medial/lateral orbital walls or removal of the orbital floor) or by means of different amounts of fat excision (usually from the inferolateral and inferomedial extraconal compartments). When decompression surgery is performed on patients affected with moderate-to-severe and inactive GO, expected beneficial effects include reduction in exophthalmos, periocular puffiness (swelling and fat prolapse) and lid retraction. Results are generally proportional to the extent of osteotomies or fat removal and are not influenced by the time elapsed between GO duration and decompression surgery [119] or by previous radiotherapy [120]. Other positive effects of decompression include a decrease in intraocular tension and relief of pain, improvement in preexisting strabismus/requirement for subsequent surgical correction and cure of postural visual obscuration in patients with orbital and optic nerve microvasculopathy. The most common complications are new onset or worsening of preexisting strabismus and globe dystopia [121].

Squint Surgery

Squint surgery aims firstly to restore fusion in primary position avoiding diplopia in down gaze and then to correct residual incomitances [122, 123]. This is achieved by means of extension of extraocular rectus muscle resections and retroequatorial myopexias. Extraocular muscle resections often need to be generous, thus tendons elongations and simultaneous conjunctival recession are mandatory for maintaining the contact arc and avoiding loss of effectiveness of recession surgery. Rarely, oblique muscles need to be operated. Topical anesthesia can be used; general anesthesia is to be considered when more muscles need to be operated or when correcting residual incomitances [121].

Eyelid Surgery

In GO, upper- and lower-lid retraction are due to a combination of inflammation, fibrosis, adrenergic stimulation and restriction of vertical rectus muscles. Exophthalmos also contributes to increasing eyelid aperture by displacing either the upper or the lower lid. Correction of upper- or lower-lid retraction implies recession of the lid retractors. Spacers are not essential for upper-lid lengthening procedures, but are necessary to provide height and the necessary stiffness to support the lower lid against gravity when severely retracted. A number of autologous, homologous, xenogenic and synthetic materials have been used, including ethanol-preserved donor sclera, upper-lid tarsus, cartilage grafts, porous polyethylene, polytetrafluoroethylene or polyester meshes. Autogenous hard-palate mucosal grafts are relatively easy to obtain, are similar to lower-lid tarsus in terms of contour, thickness and stiffness, have a mucosal surface, have no risk of rejection and undergo minimal shrinkage following grafting. Ophthalmic complications of hard-palate mucosal grafting are uncommon and morbidity at the donor site rare. Hard-palate mucosal grafts providing structural and epithelial elements are a suitable material for posterior lamella augmentation in lower-lid lengthening. Homologous acellular dermal matrix with an appropriate consistency for posterior lamella augmentation is an optimal alternative to hard-palate mucosa, but unfortunately it is not easily available throughout Europe.

Treatment of persistent upper-eyelid retraction is surgical and by far less predictable than that of the lower lid. Medical therapy with a-blocker eye drops or with postganglial adrenergic blocker drugs is not very effective or limited by side effects. Botulinum toxin is an effective option, but its effect is transient, and repeated injections are necessary. Temporary undercorrection or overcorrection can occur, and thus impaired elevation and paralysis of the orbicularis muscle (which are highly undesirable complications in GO patients in view of the risk for corneal exposure). Upper-eyelid lengthening is one of the last stages of the long-lasting and somewhat exhausting surgical rehabilitation of patients with GO. Although several surgical techniques are currently in use, the optimal approach is difficult to define. The simplest and less time-consuming technique is worth considering first. Sutureless Müllerectomy, transconjunctival free en block recession of the levator palpebrae superioris muscle and conjunctiva, or transcutaneous blepharotomy fulfill such a criterion and can be used systematically for mild-to-moderate or for moderate-to-severe degrees of upper-lid retraction [121, 124]. Cosmetic periorbital surgery in GO is not substantially different than that used for the aging face. Sculpturing or excision of the sub brow fat pad can benefit from the use of a CO₂ laser [124].

Recommendation

15 We recommend that elective rehabilitative surgery be offered to patients with GO when the disease is associated with a significant impact on visual function or QoL after the disease has been inactive for at least 6 months. If more than one surgical procedure is required, orbital decompression should precede squint surgery and be followed by lid surgery. Patients should be referred to specialized centers and specialized surgeons able to tailor different possible surgeries to the specific need of the individual patient.
**How Should Sight-Threatening GO Be Managed?**

Sight-threatening GO due to DON and/or severe corneal exposure (large epithelial and/or stromal defects) or corneal breakdown (descemetocele or frank perforation) is an emergency that should be treated immediately. Eye- ball subluxation should be regarded as a potential cause of optic nerve stretching (DON) and/or corneal breakdown. Recent development of choroidal folds (caused by indentation of the eyeball by enlarged extraocular muscles) can become a permanent cause of metamorphopsia if not treated urgently.

Very high doses of intravenous GCs (e.g. 500–1,000 mg of methylprednisolone for 3 consecutive days or on alternate days during the 1st week) are usually the first-line treatment for DON [71, 125]. This course can be repeated after a week and is effective in approximately 40% of patients with recovery of normal or near-normal vision [71, 125]. If the response is absent or poor, or when there is rapid deterioration in visual function (acuity/visual field), urgent decompression surgery should be performed. In the case of optic nerve compression, apex decompression can be better achieved by means of medial orbital wall removal; however, several studies have shown that targeting other orbital bony or fat territories is equally effective in restoring optic nerve function.

Any form of decompression surgery aimed at substantial reduction of intraorbital pressure and exophthalmos is the treatment of choice for DON because of optic nerve stretching and eyeball subluxation. Additionally, it can be beneficial for choroidal folds and severe corneal exposure when lubricants, moisturized chamber, blepharorrhaphy, tarsorrhaphy, lid lengthening and/or extraocular muscle recession fail to protect the cornea. Gluing or transplantation may be necessary when there is corneal breakdown.

### Recommendations

1. We recommend that severe corneal exposure be treated medically or by means of progressively more invasive surgeries as soon as possible in order to avoid progression to corneal breakdown. The latter should be immediately addressed surgically.

(1, ǾǾǾǾ)

17 We recommend that DON be treated immediately with very high doses of intravenous GCs (500–1,000 mg of methylprednisolone for 3 consecutive days or on alternate days during the 1st week), and urgent orbital decompression be performed if response is absent or poor within 2 weeks. Recent-onset choroidal folds and eyeball subluxation should undergo orbital decompression as soon as possible. If DON has resolved or improved after 2 weeks, pulses of weekly intravenous methylprednisolone should be continued as described for the management of moderate-to-severe and active GO.

(1, ǾǾǾǾ)

### Perspectives and Conclusions

Although GO is the most frequent extrathyroidal manifestation of Graves’ disease, it is a rare disorder [126]. However, it has a large negative impact on QoL of affected individuals even when mild [10, 127, 128]. The Amsterdam declaration, signed by numerous international experts on GO, national and international professional organizations, national and international patient associations, established general objectives aimed at minimizing GO-associated morbidity, improving patients’ QoL and preventing the occurrence of GO in at-risk individuals [129]. The recent observation that patients referred to tertiary centers have less severe and active GO [8] might indeed reflect an increased awareness of the disease and, consequently, an earlier diagnosis and management of Graves’ hyperthyroidism and GO as well as a more effective use of preventive measures, including anti-smoking measures, use of antioxidants (selenium) in mild forms, better control and stricter follow-up of thyroid dysfunction. Our understanding of the pathogenesis of GO has improved [130–132], but treatments of severe forms of the disease are still imperfect, because they do not target precisely the pathogenic mechanisms of the disease [133]. Nevertheless, steady progress is being made in this field. Randomized clinical trials have been published, either defining optimization of old treatments, such as high-dose GCs, or proposing novel biological treatments, such as rituximab. Other ongoing studies are evaluating the efficacy (and safety) of immunosuppressants, such as mycophenolate, or biologics, such as tocilizumab [134] or anti-IGF-1 receptor monoclonal antibody. Recommendations about the role of these novel agents will have to await the results of large randomized controlled studies.

### Appendix

**Participants of the EUGOGO**

Fotini Adamidou (Thessaloniki), Panagiotis Anagnostis (Thessaloniki), Goksun Ayyaz (Ankara), Claudio Azzolini (Varese), Antonella Boschi (Brussels), Claire Bournaud (Lyon), Lucy Clarke (Newcastle upon Tyne), Nicola Currò (Milan), Chantal Daumerie

DOI: 10.1159/000443828

Eur Thyroid J 2016;5:9–26

Eur Thyroid J 2016;5:9–26

Eur Thyroid J 2016;5:9–26

Eur Thyroid J 2016;5:9–26
References


Disclosure Statement

No conflict of interest to declare.


Bartalena et al.
Guidelines for GO Management

Eur Thyroid J 2016;5:9–26
DOI: 10.1159/000443828


